GlassScriptPhysician profile
Jasmine Taborn
NPI 1174281380
$3,470.15
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,105 · 2023: $1,925 · 2024: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $528.12 | 2022-2024 | Mounjaro, Emgality, Reyvow |
| Otsuka America Pharmaceutical, INC. | $266.21 | 2022-2023 | Rexulti, Nuedexta |
| Novo Nordisk INC | $258.44 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $257.11 | 2022-2024 | Farxiga, Breztri |
| Abbvie INC. | $254.15 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $220.68 | 2022 | |
| Pfizer INC. | $193.58 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.09 | 2022-2023 | Trintellix |
| Lundbeck LLC | $173.89 | 2022-2024 | Rexulti, Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $144.02 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $138.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $134.36 | 2022-2024 | |
| Amgen INC. | $116.23 | 2022-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $109.91 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Atricure, INC. | $58.84 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $57.32 | 2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.98 | 2022-2024 | Caplyta |
| Merck Sharp & Dohme LLC | $46.23 | 2023 | Verquvo, Belsomra, Lagevrio |
| Idorsia Pharmaceuticals US INC | $40.21 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $39.95 | 2023-2024 | Auvelity |
| Tris Pharma INC | $30.44 | 2023 | Dyanavel Xr |
| Exact Sciences Corporation | $27.85 | 2024 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $23.78 | 2022 | |
| Irhythm Technologies, INC. | $19.67 | 2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $19.19 | 2022 | |
| Inspire Medical Systems, INC. | $18.90 | 2023 | Inspire |
| Astellas Pharma US INC | $18.61 | 2023 | Veozah |
| Mycovia Pharmaceuticals, INC. | $15.81 | 2022 | |
| Amarin Pharma, INC. | $15.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Taborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.